Following the acquisition, SynthRx’s lead product candidate, poloxamer 188, a novel, proprietary, rheologic and antithrombotic compound, will be developed by Adventrx as ANX-188.
Adventrx CEO Brian Culley said their plan to meet with FDA this year to reach agreement on a protocol for a pivotal phase 3 study for treatment of sickle cell crisis in a pediatric population, an orphan indication.
"Beyond sickle cell, ANX-188 may have clinical utility in other acute events related to microvascular-flow abnormalities, such as heart attack, stroke and hemorrhagic shock," Culley said.